Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Biomea Fusion Inc
(NQ:
BMEA
)
6.582
+0.202 (+3.17%)
Streaming Delayed Price
Updated: 11:33 AM EST, Nov 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Biomea Fusion Inc
< Previous
1
2
3
Next >
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
November 18, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 30, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
October 15, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
October 07, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s...
From
Biomea Fusion, Inc.
Via
GlobeNewswire
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
July 31, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 08, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 03, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
June 16, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
Rosen Law Firm Encourages Biomea Fusion, Inc. Investors With Losses in Excess of $100K to Inquire About Securities Class Action Investigation – BMEA
June 13, 2024
From
The Rosen Law Firm, P.A.
Via
Business Wire
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Biomea Fusion, Inc. and Encourages Investors with Losses to Contact the Firm
June 06, 2024
From
Schall Law
Via
GlobeNewswire
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
June 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
June 03, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
May 30, 2024
BMF-219 is an investigational novel covalent menin inhibitor developed to regenerate insulin-producing beta cells
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
May 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
May 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
April 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
March 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
January 09, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.